Literature DB >> 9566584

Regional quantitation of preprodynorphin mRNA in guinea pig gastrointestinal tract.

V P Yuferov1, J A Culpepper-Morgan, K S LaForge, A Ho, M J Kreek.   

Abstract

The endogenous opioid peptide dynorphin has been shown by immunochemical studies to be widely distributed in the gastrointestinal tract. The aim of this study was to determine basal levels of preprodynorphin (ppDyn) mRNA in different regions of the gastrointestinal tract of the guinea pig. A modified sensitive and specific solution hybridization RNase protection assay was used to quantitate ppDyn mRNA, with confirmation by gel analysis of the RNase protected hybrids and PCR amplified cDNA. This method combines high sensitivity and sufficient throughput to analyze large number of samples in a single assay. Low but measurable amounts of ppDyn mRNA were detected in fundus, duodenum, jejunum, ileum, cecum, and rectum. The rectum contained significantly more ppDyn mRNA than the stomach, small bowel, and cecum. The muscularis/myenteric plexus layer of both ileum and rectum contained a higher concentration of ppDyn mRNA per microg total RNA compared to the mucosa/submucosa/submucosal plexus. However, a greater absolute amount of ppDyn mRNA (80-85%) localized to the mucosal layer. The greater absolute amount of ppDyn mRNA in the mucosal layer may indicate the presence of dynorphin in the endocrine cells of the mucosa.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9566584     DOI: 10.1023/a:1022426400545

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  37 in total

1.  Matrix-assisted laser desorption mass spectrometry of biotransformation products of dynorphin a in vitro.

Authors:  J Z Chou; M J Kreek; B T Chait
Journal:  J Am Soc Mass Spectrom       Date:  1994-01       Impact factor: 3.109

2.  Dynorphin-(1-13), an extraordinarily potent opioid peptide.

Authors:  A Goldstein; S Tachibana; L I Lowney; M Hunkapiller; L Hood
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

Review 3.  Methods used for the study of opioid receptors.

Authors:  F M Leslie
Journal:  Pharmacol Rev       Date:  1987-09       Impact factor: 25.468

4.  A solution hybridization assay for the quantitation of prodynorphin mRNA.

Authors:  L Devi; J Douglass; E Herbert
Journal:  Brain Res       Date:  1987-07       Impact factor: 3.252

5.  Differential biotransformation of dynorphin A (1-17) and dynorphin A (1-13) peptides in human blood, ex vivo.

Authors:  J Z Chou; B T Chait; R Wang; M J Kreek
Journal:  Peptides       Date:  1996       Impact factor: 3.750

6.  Modulation of peristalsis in the guinea-pig isolated small intestine by exogenous and endogenous opioids.

Authors:  S A Waterman; M Costa; M Tonini
Journal:  Br J Pharmacol       Date:  1992-08       Impact factor: 8.739

7.  Fedotozine reversal of peritoneal-irritation-induced ileus in rats: possible peripheral action on sensory afferents.

Authors:  P J Riviere; X Pascaud; E Chevalier; J L Junien
Journal:  J Pharmacol Exp Ther       Date:  1994-09       Impact factor: 4.030

Review 8.  Review article: the hypersensitive gut--peripheral kappa agonists as a new pharmacological approach.

Authors:  J L Junien; P Riviere
Journal:  Aliment Pharmacol Ther       Date:  1995-04       Impact factor: 8.171

9.  Orally administered kappa as well as mu opiate agonists delay gastrointestinal transit time in the guinea pig.

Authors:  J Culpepper-Morgan; M J Kreek; P R Holt; D LaRoche; J Zhang; L O'Bryan
Journal:  Life Sci       Date:  1988       Impact factor: 5.037

10.  Atypical prodynorphin gene expression in corticosteroid-producing cells of the rat adrenal gland.

Authors:  R Day; M K Schafer; M W Collard; S J Watson; H Akil
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

View more
  1 in total

Review 1.  Biological redundancy of endogenous GPCR ligands in the gut and the potential for endogenous functional selectivity.

Authors:  Georgina L Thompson; Meritxell Canals; Daniel P Poole
Journal:  Front Pharmacol       Date:  2014-11-28       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.